Madrigal Pharmaceuticals (MDGL)

• Market cap: $12.4B
• 1 day: -4.16%
• 5 days: 2.49%
• 1 month: 13.87%
• 3 months: 3.29%
• 6 months: 5.13%
• Year to date: -9.63%
• 1 year: 70.58%
• 5 years: 411.05%
• 10 years: 5,677.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Employees: 915